


World Journal of *Stem Cells*

World J Stem Cells 2012 April 26; 4(4): 21-27



Editorial Board

2009-2013

The *World Journal of Stem Cells* Editorial Board consists of 284 members, representing a team of worldwide experts in stem cells research. They are from 28 countries, including Australia (5), Austria (1), Belgium (3), Brazil (2), Canada (7), China (19), Czech Republic (2), Denmark (4), Finland (3), France (5), Germany (14), Hungary (3), India (3), Iran (1), Israel (4), Italy (13), Japan (18), Netherlands (4), Norway (2), Singapore (10), South Korea (15), Spain (6), Sweden (2), Switzerland (3), Turkey (2), United Arab Emirates (1), United Kingdom (15), and United States (117).

EDITOR-IN-CHIEF

LOscar Kuang-Sheng Lee, *Taipei*

STRATEGY ASSOCIATE

EDITORS-IN-CHIEF

Philippe Bourin, *Toulouse*
Andras Dinnyes, *Godollo*
Umberto Galderisi, *Napoli*
Mikhail G Kolonin, *Houston*
Balazs Sarkadi, *Budapest*

GUEST EDITORIAL BOARD

MEMBERS

Ing-Ming Chiu, *Miaoli*
Chie-Pein Chen, *Taipei*
Ju Jyh-Cherng, *Taichung*
Hossein Hosseinkhani, *Taipei*
Steven Shoei-Lung Li, *Kasohsiung*
Tzu-Hao Wang, *Tao-Yuan*

MEMBERS OF THE EDITORIAL BOARD



Australia

Jeremy M Crook, *Melbourne*
Alice Pébay, *Victoria*
Kuldip S Sidhu, *Sydney*
Ernst Wolvetang, *Brisbane*
Xin-Fu Zhou, *Adelaide*



Austria

Ludwig Aigner, *Salzburg*



Belgium

Yves Beguin, *Liege*

Mieke Geens, *Brussels*

Najimi Mustapha, *Brussels*



Brazil

Niels Olsen Saraiva Câmara, *São Paulo*
Naiara Zoccal Saraiva, *Jaboticabal*



Canada

Borhane Annabi, *Montreal*
Rosario Isasi, *Quebec*
Xiao-Yan Jiang, *Vancouver*
Seung U Kim, *Vancouver*
Ren-Ke Li, *Toronto*
Jeffrey A Medin, *Toronto*
Kursad Turksen, *Ottawa*



China

Xiu-Wu Bian, *Chongqing*
Yong Dai, *Shenzhen*
Zhong-Chao Han, *Tianjin*
Zhang Hao, *Beijing*
Anskar YH Leung, *Hong Kong*
Gang Li, *Hong Kong*
Gui-Rong Li, *Hong Kong*
Kai-Yan Liu, *Beijing*
Yi-Jia Lou, *Hangzhou*
Xue-Tao Pei, *Beijing*
Jing-He Tan, *Tan-An*
Jin-Fu Wang, *Hangzhou*
Yun-Hai Zhang, *Hefei*



Czech Republic

Petr Dvorak, *Brno*
Jaroslav Mokry, *Hradec Kralove*



Denmark

Basem M Abdallah, *Odense*
Poul Maddox-Hyttel, *Frederiksberg*
Lin Lin, *Tjele*
Soren Paludan Sheikh, *Odense*



Finland

Jukka Partanen, *Helsinki*
Petri Salven, *Helsinki*
Heli Skottman, *Tampere*



France

Alain Chapel, *Paris*
Gwendal Lazennec, *Montpellier*
Muriel Perron, *Paris*
Xavier Thomas, *Lyon*



Germany

James Adjaye, *Berlin*
Christian Buske, *Ulm*
Denis Corbeil, *Dresden*
Frank Edenhofer, *Bonn*
Ursula Margarethe Gehling, *Langen*
Eric Gottwald, *Eggenstein-Leopoldshafen*
Jorg Kleeff, *Munich*
Gesine Kögler, *Düsseldorf*
Nan Ma, *Rostock*
Ulrich Martin, *Hannover*
Heinrich Sauer, *Giessen*
Richard Schäfer, *Tübingen*
Sonja Schrepfer, *Hamburg*
Wolfgang Wagner, *Aachen*

**Hungary**Ferenc Uher, *Budapest***India**Gurudutta U Gangenahalli, *Delhi*
Asok Mukhopadhyay, *New Delhi*
Anjali Suhas Shiras, *Maharashtra***Iran**Masoud Soleimani, *Tehran***Israel**Zeev Blumenfeld, *Haifa*
Rachel Sarig, *Rehovot*
Avichai Shimoni, *Tel-Hashomer*
Shimon Slavin, *Tel Aviv***Italy**Carlo Alberto Beltrami, *Udine*
Clotilde Castaldo, *Naples*
Carmelo Carlo-Stella, *Milano*
Massimo Dominici, *Modena*
Stefania Filos, *Naples*
Angela Gritti, *Milano*
Roberta Morosetti, *Rome*
Felicita Pedata, *Florence*
Anna Chiara Piscaglia, *Rome*
Stefano Pluchino, *Milan*
Caterina AM La Porta, *Milan*
Domenico Ribatti, *Bari***Japan**Tomoki Aoyama, *Kyoto*
Susumu Ikehara, *Osaka*
Taro Matsumoto, *Tokyo*
Yuko Miyagoe-Suzuki, *Tokyo*
Hiroyuki Miyoshi, *Tsukuba*
Takashi Nagasawa, *Kyoto*
Tetsuhiro Niidome, *Kyoto*
Toshio Nikaido, *Toyama*
Kohzo Nakayama, *Nagano*
Tsukasa Ohmori, *Tochigi*
Caterina AM La Porta, *Milan*
Kumiko Saeiki, *Tokyo*
Kazunobu Sawamoto, *Aichi*
Mikiko C Siomi, *Tokyo*
Yoshiaki Sonoda, *Osaka*
Takashi Tada, *Kyoto*
Kotaro Yoshimura, *Tokyo*
Louis Yuge, *Hiroshima***Netherlands**Dirk Gijsbert de Rooij, *Amsterdam*Christine Mummery, *Leiden*
Frank JT Staal, *Leiden*
Marten Piet Smidt, *Utrecht***Norway**Brynjar Foss, *Stavanger*
Berit Bølge Tysnes, *Bergen***Singapore**Yu Cai, *Research Link*
Tong Cao, *Singapore*
Jerry Chan, *Singapore*
Gavin Stewart Dawe, *Medical Drive*
Chan Kwok-Keung Ken, *Singapore*
Chan Woon Khiong, *Singapore*
Steve KW Oh, *Singapore*
Seeram Ramakrishna, *Singapore*
Herbert Schwarz, *Singapore*
Shu Wang, *Biopolis Way***South Korea**Jong Wook Chang, *Seoul*
Chong-Su Cho, *Seoul*
Ssang-Goo Cho, *Seoul*
Ho Jae Han, *Gwangju*
Ki-Chul Hwang, *Seoul*
Kyung-Sun Kang, *Seoul*
Haekwon Kim, *Seoul*
Hoeon Kim, *Daejeon*
Mee Kum Kim, *Seoul*
Yoon Jun Kim, *Seoul*
Soo-Hong Lee, *Seoul*
Dae-Sik Lim, *Daejeon*
Byung Soon Park, *Seoul*
Sun U Song, *Incheon*
Seung Kwon You, *Seoul***Spain**Fernando Cobo, *Granada*
Sabrina C Desbordes, *Barcelona*
Marta Muñoz Llamosas, *España*
Maria P De Miguel, *Madrid*
María Dolores Miñana, *Valencia*
Felipe Prosper, *Navarra***Sweden**M Quamrul Islam, *Linköping*
Stefan Karlsson, *Lund***Switzerland**Thomas Daikeler, *Basel*
Sabrina Mattoli, *Basel*
Arnaud Scherberich, *Basel***Turkey**Alp CAN, *Ankara*
Berna Arda, *Ankara***United Arab Emirates**Sherif M Karam, *Al-Ain***United Kingdom**Dominique Bonnet, *London*
Kristin Mary Braun, *London*
Wei Cui, *London*
David C Hay, *Edinburgh*
Wael Kafienah, *Bristol*
Francis L Martin, *Lancaster*
Mike Modo, *London*
Donald Palmer, *London*
Dame Julia Polak, *London*
James Alexander Ross, *Edinburgh*
Alastair James Sloan, *Cardiff*
Virginie Sottile, *Nottingham*
Hong Wan, *London*
He-Ping Xu, *Aberdeen*
Rike Zietlow, *Cardiff***United States**Gregor Barr Adams, *Los Angeles*
Kinji Asahina, *Los Angeles*
Craig S Atwood, *Madison*
Debabrata Banerjee, *New Brunswick*
Aline M Betancourt, *New Orleans*
Surinder Kumar Batra, *Omaha*
Bruce Alan Bunnell, *New Orleans*
Jason A Burdick, *Philadelphia*
Anthony WS Chan, *Atlanta*
Rebecca J Chan, *Indianapolis*
G Rasul Chaudhry, *Rochester*
Jonathan Donald Chesnut, *Carlsbad*
Herman S Cheung, *Coral Gables*
Kent W Christopherson II, *Chicago*
David Wade Clapp, *Indianapolis*
Rubin Clinton, *New York*
Claudius Conrad, *Boston*
Charles Samuel Cox, *Houston*
Marcos de Lima, *Houston*
Douglas C Dean, *Louisville*
Goberdhan Dimri, *Evanston*
David Dingli, *Rochester*
Fu-Liang Du, *Vernon*
Todd Evans, *New York*
Toshihiko Ezashi, *Columbia*
Vincent Falanga, *Alternate*
Ira J Fox, *Pittsburgh*
Markus Frank, *Boston*
Sanga Gehmert, *Houston*
Yong-Jian Geng, *Houston*
Joseph C Glorioso, *Pittsburgh*
Kristbjorn Orri Gudmundsson, *Frederick*
Yan-Lin Guo, *Hattiesburg*
Tong-Chuan He, *Chicago*
Lorraine Iacovitti, *Philadelphia*
Kunlin Jin, *Novato*

Michael R King, *Ithaca*
Uma Lakshmi pathy, *Carlsbad*
Hillard Michael Lazarus, *Shaker Heights*
Techung Lee, *Buffalo*
Robert C Miller, *Rochester*
Tao-Sheng Li, *Los Angeles*
Xiao-Nan Li, *Houston*
Ching-Shwun Lin, *San Francisco*
P Charles Lin, *Nashville*
Su-Ling Liu, *Ann Arbor*
Aurelio Lorico, *Las Vegas*
Jean-Pierre Louboutin, *Philadelphia*
Bing-Wei Lu, *Stanford*
Qing Richard Lu, *Dallas*
Nadya L Lumelsky, *Bethesda*
Hong-Bo R Luo, *Boston*
Hinh Ly, *Atlanta*
Teng Ma, *Tallahassee*
Kenneth Maiese, *Detroit*
Robert L Mauck, *Philadelphia*
Glenn Edwards Mcgee, *New York*
Murielle Mimeault, *Omaha*
Guo-Li Ming, *Baltimore*
Masato Nakafuku, *Cincinnati*
Christopher Niyibizi, *Hershey*
Seh-Hoon Oh, *Gainesville*
Frank Pajonk, *Los Angeles*

Gregory M Pastores, *New York*
Derek A Persons, *Memphis*
Donald G Phinney, *Florida*
Donald George Phinney, *New Orleans*
Dimitris G Placantonakis, *New York*
George E Plopper, *Troy*
Derek Radisky, *Jacksonville*
Murugan Ramalingam, *Gaithersburg*
Pranela Rameshwar, *Newark*
Jeremy N Rich, *Cleveland*
Angie Rizzino, *Omaha*
Paul Ronald Sanberg, *Tampa*
Gerald Phillip Schatten, *Pittsburgh*
Ashok Kumar Shetty, *Durham*
Igor I Slukvin, *Madison*
Shay Soker, *Winston-Salem*
Hong-Jun Song, *Baltimore*
Kenichi Tamama, *Columbus*
Dean G Tang, *Smithville*
Hugh S Taylor, *New Haven*
Jonathan L Tilly, *Boston*
Jakub Tolar, *Minneapolis*
Deryl Troyer, *Manhattan*
Scheffer Chuei-Goong Tseng, *Miami*
Lyuba Varticovski, *Bethesda*
Tandis Vazin, *Berkeley*
Kent E Vrana, *Hershey*

Lyuba Varticovski, *Bethesda*
Qi Wan, *Reno*
Charles Wang, *Los Angeles*
Guo-Shun Wang, *New Orleans*
Zack Z Wang, *Scarborough*
David Warburton, *Los Angeles*
Li-Na Wei, *Jackson Hall*
Andre Van Wijnen, *Worcester*
Marc Adrian Williams, *Rochester*
Joseph C Wu, *Stanford*
Li-Zi Wu, *Gainesville*
Sean M Wu, *Boston*
Yan Xu, *Pittsburgh*
Jun Yan, *Louisville*
Jing Yang, *Orange*
Li-Jun Yang, *Florida*
Phillip Chung-Ming Yang, *Stanford*
Pampee Paul Young, *Nashville*
Hong Yu, *Miami*
Seong-Woon Yu, *East Lansing*
Xian-Min Zeng, *Novato*
Bao-Hong Zhang, *Greenville*
Ying Zhang, *Baltimore*
Xue-Sheng Zheng, *Massachusetts*
X Long Zheng, *Philadelphia*
John F Zhong, *Los Angeles*

BRIEF ARTICLE

21 Human umbilical mesenchymal stem cell and its adipogenic differentiation:
Profiling by nuclear magnetic resonance spectroscopy

Xu ZF, Pan AZ, Yong F, Shen CY, Chen YW, Wu RH

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Stem Cells*

APPENDIX I Meetings

 I-V Instructions to authors

ABOUT COVER Xu ZF, Pan AZ, Yong F, Shen CY, Chen YW, Wu RH.
 Human umbilical mesenchymal stem cell and its adipogenic differentiation:
 Profiling by nuclear magnetic resonance spectroscopy.
World J Stem Cells 2012; 4(4): 21-27
<http://www.wjgnet.com/1948-0210/full/v4/i4/21.htm>

AIM AND SCOPE *World Journal of Stem Cells (World J Stem Cells, WJSC, online ISSN 1948-0210, DOI: 10.4252), is a Monthly open-access peer-reviewed journal supported by an editorial board consisting of 284 experts in stem cell research from 28 countries.*
 The major task of *WJSC* is to rapidly report original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including embryonic stem cells, neural stem cells, hematopoietic stem cells, mesenchymal stem cells, tissue-specific stem cells, cancer stem cells, the stem cell niche, stem cell genomics and proteomics, and translational and clinical research. In a word, papers published in *WJSC* will cover the biology, culture, and differentiation of stem cells from all stages of development from germ cell to embryo and adult.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Jin-Lei Wang*
 Responsible Electronic Editor: *Xiao-Mei Zheng*
 Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Jin-Lei Wang*
 Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Stem Cells

ISSN
 ISSN 1948-0210 (online)

LAUNCH DATE
 December 31, 2009

FREQUENCY
 Monthly

EDITING
 Editorial Board of *World Journal of Stem Cells*
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: +86-10-85381891
 Fax: +86-10-85381893
 E-mail: wjsc@wjgnet.com
<http://www.wjgnet.com>

EDITOR-IN-CHIEF
Oscar Kuang-Sheng Lee, MD, PhD, Professor,

Medical Research and Education of Veterans General Hospital-Taipei, No. 322, Sec. 2, Shih-pai Road, Shih-pai, Taipei, 11217, Taiwan, China

EDITORIAL OFFICE
 Jin-Lei Wang, Director
World Journal of Stem Cells
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: +86-10-85381891
 Fax: +86-10-85381893
 E-mail: wjsc@wjgnet.com
<http://www.wjgnet.com>

PUBLISHER
 Baishideng Publishing Group Co., Limited
 Room 1701, 17/F, Henan Building,
 No.90 Jaffe Road, Wanchai,
 Hong Kong, China
 Fax: +852-31158812
 Telephone: +852-58042046
 E-mail: bpg@baishideng.com
<http://www.wjgnet.com>

PUBLICATION DATE
 April 26, 2012

COPYRIGHT
 © 2012 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
 All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
 Full instructions are available online at http://www.wjgnet.com/1948-0210/g_info_20100313165700.htm

ONLINE SUBMISSION
<http://www.wjgnet.com/1948-0210office/>

Human umbilical mesenchymal stem cell and its adipogenic differentiation: Profiling by nuclear magnetic resonance spectroscopy

Zhi-Feng Xu, Ai-Zhen Pan, Fang Yong, Chong-Yang Shen, Yao-Wen Chen, Ren-Hua Wu

Zhi-Feng Xu, Yao-Wen Chen, Ren-Hua Wu, Department of Medical Imaging, the 2nd Affiliated Hospital, Medical College of Shantou University, Shantou 515041, Guangdong Province, China

Zhi-Feng Xu, Ai-Zhen Pan, Fang Yong, Department of Medical Imaging, The First People's Hospital of Foshan, Foshan 528000, Guangdong Province, China

Chong-Yang Shen, Multidisciplinary Research Center of Shantou University, Shantou 515041, Guangdong Province, China

Author contributions: Xu ZF and Pan AZ contributed equally to this paper; Xu ZF performed the majority of experiments and wrote the manuscript; Shen CY provided vital reagents and stem cells; Pan AZ and Yong F were involved in editing the manuscript; Chen YW provided some materials and equipment; Wu RH designed the study and provided financial support for this work.

Supported by Grants from the National Natural Science Foundation of China (Key program 30930027) and Natural Science Foundation of Guangdong Province (No. 8151503102000032)

Correspondence to: Ren-Hua Wu, Professor, Department of Medical Imaging, the 2nd Affiliated Hospital, Medical College of Shantou University, Shantou 515041, Guangdong Province, China. rhwu@stu.edu.cn

Telephone: +86-754-88915674 Fax: +86-754-88915674

Received: August 11, 2011 Revised: February 21, 2012

Accepted: March 3, 2012

Published online: April 26, 2012

Abstract

AIM: To study the metabolic profile of human umbilical mesenchymal stem cells (HUMSC) and adipogenic differentiation by nuclear magnetic resonance (NMR) spectroscopy.

METHODS: HUMSC isolated from human umbilical cord stroma were induced to adipocytes over 2 wk by adding dexamethasone, 3-isobutyl-1-methylxanthine, indomethacin, and insulin to the culture medium. Adipogenic differentiation was confirmed by Red O staining and transcription-polymerase chain reaction. Perchloric acid extracts of the HUMSCs and adipocytes (about $7 \times$

10^6) were characterized for metabolites by using *in vitro* high resolution 9.4T NMR spectroscopy.

RESULTS: Several major metabolites, such as: choline, creatine, glutamate and myo-inositol, acetate, and some fatty acids/triglycerides, were observed in the MR spectroscopic pattern of HUMSCs and their adipogenic differentiation. HUMSCs are characterized by an unusually low number of NMR-detectable metabolites, high choline, acetate, glutamate and creatine content. However, the metabolic profiles of adipogenic differentiation demonstrated considerably higher methionine and fatty acids, and non-detectable creatine.

CONCLUSION: The biomarkers of HUMSCs and adipocytes were obtained and assigned. NMR spectroscopy will be a promising tool for monitoring stem cell differentiation.

© 2012 Baishideng. All rights reserved.

Key words: Human umbilical mesenchymal stem cell; Adipogenic differentiation; MR spectroscopy; Biomarker

Peer reviewer: Arash Zaminy, PhD, Anatomy and Cell Biology Department, Medicine School, Shahid Beheshti University of Medical Sciences, Evine 1985717443, Tehran, Iran

Xu ZF, Pan AZ, Yong F, Shen CY, Chen YW, Wu RH. Human umbilical mesenchymal stem cell and its adipogenic differentiation: Profiling by nuclear magnetic resonance spectroscopy. *World J Stem Cells* 2012; 4(4): 21-27 Available from: URL: <http://www.wjgnet.com/1948-0210/full/v4/i4/21.htm> DOI: <http://dx.doi.org/10.4252/wjsc.v4.i4.21>

INTRODUCTION

Cellular-based therapies using mesenchymal stem cells (MSCs) are being evaluated as promising treatment op-

tions for many diseases and injuries. MSCs are of great interest in regenerative medicine, because of their properties of pluripotency^[1,2], and low immunologic rejection. They are capable of reconstructing a tissue and a coordinating function. Human umbilical MSCs (HUMSC) isolated from human umbilical cord Wharton's Jelly called fetal appendage, were considered to be a new stem cell line for cellular-based therapy^[3]. Increasingly, nowadays, researches are focusing on the HUMSC. Extensive gene expression and immunocytochemistry studies were recently performed on HUMSC, but despite the demanding effort and expense involved, they yielded surprisingly incoherent results^[4]. However, so far, the information about metabolites of HUMSC is limited, and there are unexplored areas in this field. HUMSC should be studied further to obtain more information before considering clinical applications.

Nuclear magnetic resonance (NMR) spectroscopy can act as a powerful window into the metabolic machinery of cells^[5-7]. Because of its noninvasive nature and high chemical specificity, it is well suited for studying and quantifying cellular metabolism in tissue and organ, reflecting levels of endogenous metabolites involved in key cellular pathways. Recently, NMR spectroscopy *in vitro* has been shown to readily identify many cell types under culture conditions on the basis of their metabolic properties; such as neural stem cells and embryonic stem cells^[7], neural progenitor cells^[8], bone MSCs (BMSCs)^[9], and cell apoptosis^[10]. The changes in the intracellular metabolites associated with the pathological change, can be detected by NMR or MR spectroscopy, *in vitro* and *in vivo*, respectively. MRS studies *in vitro* provide a more comprehensive metabolic profile of the low molecular weight components. In the present study, we attempt to identify the metabolic profile of HUMSC, and characterize the changes to intracellular metabolites of HUMSC undergoing adipogenic differentiation, using 9.4T high-resolution 1H NMR spectroscopy. The results show that the MR spectroscopic pattern of HUMSC was identified, and the change in metabolites was obvious after adipogenic differentiation. Furthermore, it will provide a theoretical basis for future HUMSC monitoring after transplantation by using *in vivo* MR spectroscopy.

MATERIALS AND METHODS

HUMSCs and adipogenic differentiation

The HUMSCs were obtained from human umbilical cord stroma, received as a gift from Stem Cell Laboratory (Multidisciplinary Research Center of Shantou University, China). HUMSCs were cultivated as described^[2]. 80%-85% subconfluent HUMSCs from passage 4 in culture underwent a differentiation process described earlier by Karahuseyinoglu *et al.*^[11]. Briefly, the HUMSCs were induced for adipogenic differentiation by an administration of 1 $\mu\text{mol/L}$ dexamethasone, 500 $\mu\text{mol/L}$ 3-isobutyl-1-methylxanthine, 60 $\mu\text{mol/L}$ indomethacin, and 5 $\mu\text{g/mL}$ insulin in DMEM-low glucose (low glucose, 1 g/L) supplemented with 10% fetal bovine serum.

Induced cells were maintained at 37 °C in 5% CO₂/95% air incubator under sterile conditions, and the culture medium was changed every 3-4 d.

Adipogenic differentiation identification with Red-O staining and reverse reverse transcriptase-polymerase chain reaction

When the cells were induced for adipogenic differentiation for 2 wk, the culture medium was changed 12 h before Oil Red-O staining. After removing the medium, the cells were washed with PBS 3 times, after that ten percent buffered formalin-fixed cells (15 min at room temperature) were stained by 1% (wt/vol) oil red O in 60% isopropanol for 15 min. After washing cells with distilled H₂O 3 times, the cells were observed under a microscope. In order to confirm that the lipid body formed is mainly due to adipogenic induction, the mRNA expression test was required. Total cellular RNA was isolated using the RNeasy mini kit (Qiagen, GmbH, and Hilden, Germany) according to the manufacturer's instructions. Several main primers such as: peroxisome proliferator-activated receptor (PPAR)- γ , acyl-CoA synthetase (ACS), and the enzyme lipoprotein lipase (LPL), *etc.*, were used for reverse reverse transcriptase-polymerase chain reaction (RT-PCR); the expression level of GAPDH was used as the house keeping gene control. We described the examination, in detail, in a previous publication^[12].

Cells extracts and 1H-NMR spectroscopy data acquisition

When the HUMSCs grew to sufficient numbers for the experiment (about 7×10^6) and cell differentiation induced for 2 wk, the cells were harvested quickly with a vulcanite scraper and washed three times with PBS to remove potential medium residue. The cells were collected for future study by centrifugation (1200 r/min at 4 °C) for 8 min. Metabolite extraction was performed on ice in 2 mL perchloric acid PCA (0.5 mmol/L) for these cell pellets. Briefly, the samples were sonicated (BILON99-11DL Instruments, China) for 6 min and then the sample pH values were neutralized with ice-cold KOH (1 mmol/L) and PCA (0.5 mmol/L). Then the mixture was centrifuged (BECKMAN USA) for 25 min (15 000 r/min at 4 °C). The resulting supernatant was lyophilized into powder, and then stored at -80 °C for 1H NMR analysis. Weighed 10 mg lyophilized extracts were transferred to 5 mm NMR tubes and redissolved in 500 μL D₂O containing 0.5 mmol/L 2, 2-3, 3-tetradetero-trimethylsilylpropionate (TMSP), which was used as an external standard [0.00 part per million (ppm)] for sample quantification and assignment of the metabolites. The samples were analyzed on an *in vitro* 9.4 T high resolution magnetic resonance spectrometer (Bruker Avance 400 MHz) at 27 °C. NMR spectra were obtained using presaturation of the residual water protons in the solvent with the Bruker ZGPR pulse program. The spectral parameters were: sweep width = 5 kHz, data size = 4096 points, TR = 20 s and the number of scans = 128. The chemical shift was




Figure 1 Human umbilical mesenchymal stem cells, adipogenic differentiation and red-o staining. A is the human mesenchymal stem cells at passage 4, the cells assumed a more spindle-shaped, fibroblastic morphology; B-D demonstrate the human umbilical mesenchymal stem cells (HUMSCs) after 2 wk adipogenic differentiation without and with the Red-O staining, respectively. The differentiated cells' shape had transformed into an ovoid/round morphology and there were abundant lipid droplets presented in the cell periphery; E is the HUMSCs with Red-O staining without differentiation, no lipid body is visible.

assigned according to the internal standard (TMSP), and was analyzed by MestRe-c 4.3.

Quantification of the interesting metabolites

We compared the integration of TMSP signal with intracellular metabolites after baseline and phase correction for quantification. The concentration of the metabolite was calculated according to this equation^[10]. $\text{Metabolite} = [\text{Square}(\text{metabolite})]/[\text{square}(\text{TMSP})] \times [\text{Number of protons of metabolite}/9] \times \text{TMSP}$. Square (metabolite) and square (TMSP) stand for the area of metabolite peak of interest and TMSP signals; (TMSP) and (metabolite) represent the concentration of TMSP and metabolites, respectively; 9 is the number of protons giving rise to the TMSP resonance. Statistical comparisons of the metabolite level in HUMSC and differentiated cells were made using the SPSS13.0 software. Absolute concentrations were given as mean \pm SD and statistically analyzed using the Student's *t*-test for the comparison of two groups, with $P < 0.05$ considered to be significant.

RESULTS

The HUMSCs isolated from human umbilical cord stroma were serial sub-cultivation and adipogenic differentiation induced. Figure 1A shows HUMSCs as a monolayer of large, fat cells (about 30 μm in diameter) in culture medium. As the HUMSCs approached confluence, they assumed a more spindle-shaped, fibroblastic morphology. The onset of phenotypic changes was noticed as early as

the first days of induction. Figure 1B shows that after 14 d adipogenic treatment the cell shape had transformed into an ovoid/round morphology, together with increased number and size of mobile lipid droplets which coalesced, and showed a tendency to accumulate in the cell periphery. Figure 1C and D are the results for Oil Red-O stain of the HUMSCs after and before undergoing adipogenic induction. After 14 d under adipogenic conditions, the lipid droplets in the cytoplasm were clearly visualized, with Oil Red-O stain. However, no lipid body was observed in the cytoplasm of the HUMSCs before differentiation. Figure 2 demonstrates that the PPAR- γ , ACS, FABP4, LPL gene expression increased with adipogenic differentiation induced for 0, 7 and 14 d. At 14 d, all the above genes were expressed to different degrees. Figure 3A and B represent a typical ^1H NMR spectrum of HUMSCs before and after adipogenic treatment, respectively. There are two obviously distinct spectra in 0.00-3.50 ppm region of the spectrum. Several resonance signals seem particularly outstanding within 0.00-3.50 ppm chemical shifts; for instance, choline compound (3.21-3.24 ppm) consists of choline, phosphocholine and glycerphosphocholine, creatine (3.05 ppm), acetate (1.91 ppm), methionine (2.19 ppm), succinate (2.41 ppm), lactate (1.31 ppm) and fatty acid (1.28 ppm), and so on. These visible metabolites in the two spectra and their corresponding chemical shifts, also including the respective groups contributing to these signals, are all shown in Table 1. It is noticeable that in the spectra of HUMSCs with and without differentiation, the amplitudes of metabolic resonances are

Table 1 Intracellular metabolites and their chemical shifts, before and after differentiation of human umbilical mesenchymal stem cells (Sitter *et al.*^[20], 2002 and Govindaraju *et al.*^[21], 2000)

Metabolites	1H or spin	Chemical shift (ppm)
Valine (Val)	γCH3	0.98 1.02
Fatty acids	-CH2-(CH2) _n -CH2-	1.28
Lactate (Lac)	CH3	1.32
Fatty acids	(-CH2-CH3)	1.35
Fatty acids	(-CO-CH2-CH2-)	1.54
Acetate (Ace)	CH3	1.92
Glutamate (Glu)	βCH2 γCH2	2.05 2.34
Methionine (Meth)	βCH2	2.19
Succinate (Suc)	(α,βCH2)	2.41
Fatty acids	-CH=CH-CH2-CH=CH-	2.75
Creatine (Cr)	CH3	3.05
Choline (Cho)	N-(CH3)3	3.21
Phosphocholine (PC)	N-(CH3)3	3.22
Glycerphosphocholine (GPC)	N-(CH3)3	3.23
Taurine (Tau)	N-CH2 S-CH2	3.27 3.43
Myo-Inositol (Myo)	C1H C3H	3.54

distinct. Quantification of metabolite concentrations was performed; the levels of intracellular metabolites, such as choline (Cho), creatine (Cr), glutamate (Glu) and acetate (Ace) all decreased, with an increased level of methionine (Meth), succinate (Suc) and fatty acids after HUMSCs differentiation for 2 wk. Intracellular choline, acetate, glutamate and creatine reduced from 6.3 ± 0.68 , 0.97 ± 0.23 , 0.3 ± 0.05 and 0.1 ± 0.02 mmol/L to 1.1 ± 0.06 ($P < 0.01$), 0.45 ± 0.1 ($P < 0.01$), 0.16 ± 0.08 mmol/L ($P < 0.05$) and non-detected, respectively. Inversely, the methionine, succinate increased from 0.03 ± 0.01 , 0.11 ± 0.02 mmol/L to 0.12 ± 0.05 ($P < 0.01$) and 0.15 ± 0.05 mmol/L ($P > 0.05$), in addition the fatty acids also increased remarkably (Table 2).

DISCUSSION

HUMSCs, pluripotent progenitors derived from human umbilical cord Wharton's Jelly, were capable of differentiating into the mesoderm lineage, such as adipocytes, chondrocytes and osteoblasts^[1,2]. The adipogenic induction in HUMSCs was described by Karahuseyinoglu *et al.*^[11], and was simply verified by Oil Red-O, a histological stain used to detect neutral lipids. In this study, a significant quantity of lipid particles occurred after 3 d in HUMSCs undergoing adipogenic differentiation. After 14 d adipogenic treatment, mobile lipid droplets of increased number and size, stained positive with Oil Red O stain, were observed gathering in the cytoplasm. However, previous studies also indicated that lipid bodies are a reference for apoptosis evaluation^[13,14]. Therefore, in the present study, the adipogenesis-specific genes, such as PPAR-γ, LPL, ACS and FABP4 were confirmed. The PPAR-γ is important in initiating the transcription of adipogenic genes and this protein can be activated by fatty acids. In lipoprotein metabolism, LPL breaks the large molecules of triglycer-




Figure 2 Reverse reverse transcriptase-polymerase chain reaction of the human umbilical mesenchymal stem cells and adipogenic differentiation. After adipogenic differentiation induced for 1 and 2 wk, the mRNA expression of adipocyte-specific genes, such as peroxisome proliferator-activated receptor (PPAR-γ), FABP4, acyl-CoA synthetase (ACS), and lipoprotein lipase (LPL) are visible more or less. This expression is absent in human umbilical mesenchymal stem cells, without differentiation.

ides into chylomicron and very light density lipoprotein into small molecules of fatty acids to facilitate absorption into tissues through the endothelium of the capillary. Synthesis of LPL is found to be dominant in adipose tissue. In the present study, RT-PCR was performed at HUMSCs adipogenic induction at 7th and 14th day. This demonstrated that the expression of PPAR-γ, ACS and LPL were all increased gradually, but at different rates. In the present study we found: (1) HUMSCs are promising seeding cells in tissue engineering, as they can be differentiated into mature fat cells; and (2) the method used for inducing HUMSCs to become adipocytes was successful.

Biological construction of the metabolome in an organism is now fully understood. The metabolites located "downstream" of the genome will fluctuate naturally along with changes in genome, transcription, proteome^[5], and enzyme activation. Thus, metabolites contain abundant biological information and indicate cells' physiological function and activity. Several metabolites are usually predominant in the spectrum of biological samples; these metabolites include Cho, Glu, Cr and Lac, which demonstrate different physiological function^[15]. Whereas, some metabolites are the typical biomarker for a particular cell line, this can contribute to identify, trace and purify that specific cell line. One of the notable findings in present series was that the HUMSC spectrum pattern was established; Cho, Glu, Cr, MI and Lac peaks were predominant. The biggest difference between the HUMSC spectrum and the adipocyte spectrum is that some peaks located at 1.35 ppm, 1.54 ppm and 2.75 ppm arose in the latter. A previous study showed that these resonances were attributable to fatty acid or neutral lipid^[16]. However, in the present study, we assumed that they most likely arose from the neutral lipid, especially triglycerides, accumulating in lipid bodies in the cells. Abundant cytoplasmic lipid bodies were observed in HUMSCs undergoing adipogenic differentiation. The relationship between 1H NMR-visible mobile lipid domains with cytoplasmic lipid bodies had been revealed by many previous studies^[17,18].

Table 2 Concentrations of major metabolites in mesenchymal stem cells and mesenchymal stem cell-differentiated cells

Metabolites	Cho (mmol/L)	Ace (mmol/L)	Cr (mmol/L)	Glu (mmol/L)	Meth (mmol/L)	Suc (mmol/L)
MSCs (n = 6)	6.30 ± 0.68	0.97 ± 0.23	0.10 ± 0.02	0.30 ± 0.05	0.03 ± 0.01	0.11 ± 0.02
Differentiated cells (n = 4)	1.10 ± 0.06	0.45 ± 0.10	ND	0.16 ± 0.08	0.15 ± 0.05	0.12 ± 0.05
P value	< 0.01	< 0.01	< 0.01	< 0.01	< 0.01	> 0.05

MSCs: Mesenchymal stem cells; Cho: Choline; Ace: Acetate; Cr: Creatine; Glu: Glutamate; Meth: Methionine; Suc: Succinate.




Figure 3 Metabolic profile of human umbilical mesenchymal stem cells before and after adipogenic differentiation. A and B are the nuclear magnetic resonance Spectrums of human umbilical mesenchymal stem cells (HUMSCs) and adipogenic differentiation, respectively. The two spectrums demonstrated that the levels of intracellular metabolites, such as choline, creatine, glutamate and acetate all decreased with the increased level of methionine, succinate and fatty acids after the HUMSCs differentiation 2 wk.

Here, there would be one question; whether the PCA extraction is unable to get comprehensive lipid signals in the cells. However, to a certain extent, some information of water-soluble fatty acids or neutral lipid can be accessed. We found, typically, that these lipid signals arose

in the spectra of adipogenic differentiation. The level of these metabolites would vary with the specific cell line and process. The level of metabolites would vary with the process of cell development, differentiation and damage due to functional gene expression, transcription level

and enzyme activation changes. Interestingly, we found that, in HUMSCs undergoing adipogenic differentiation, the reduction of Cr, Cho, Ace and Glu was remarkable. It indicates that the intracellular metabolites will meet the requirements of the cell's function and activity variation. We presumed the metabolite variation can be explained by: (1) Initially, there is growth arrest of proliferating pre-adipocytes, which was demonstrated by Hansen *et al.*^[19]. The PPAR- γ activation is the main reason for promoting growth arrest and the establishment of the differentiated adipocyte phenotype^[19]. In the present study, PPAR- γ expression increased after 2 wk adipogenic differentiation. Lower levels of metabolites might be associated with cells in growth arrest; and (2) it is expected that adipocytes have much lower intracellular metabolite levels compared to HUMSCs. The results appeared to be similar to that of Shi *et al.*^[9], so that it seemed that this had little novelty value but, in fact, this is not the case. Several important distinctions were obvious. Firstly, human UMSCs were used in this study, instead of Balb/c mouse BMSCs, namely, the metabolic profile of HUMSCs was established. It is surprising that the metabolic features of an MSC line in human and mouse was almost the same. Therefore, combining both studies, showed that using mouse MSCs to replace human MSCs for pre-clinical MRS research is feasible. Secondly, using RT-PCR, as performed in this research, to verify adipogenic differentiation was scientifically exact. Moreover, a routine PCA extraction, not HRMAS 1H-NMR spectroscopy, was used in present series, although the spectrum of MSC with and without adipogenic differentiation was similar. The two experimental results confirm each other. Although many results of the two studies were similar, the concentration of the metabolites is lower in the present series. We hypothesized that these distinctions may be attributed to differences in the detection methods used, as well as in the differentiation time. Using high-resolution 1H NMR spectroscopy for cell extracts, metabolite loss would be greater. Even more surprisingly, methionine was increased after differentiation, which had not been reported before. As an essential amino acid, the methionine consumption decreased with the cell differentiation stage, but uptake was not decreased correspondingly. This may be an anomaly in the present study, further research is required.

However, there are some limitations to the current study. Firstly, a large number of cultured cells are required to achieve excellent NMR resonance intensity. These are *in vitro* studies, so the results cannot really reflect the *in vivo* metabolism of HUMSCs. Furthermore, as a routine method, PCA extraction cannot provide overall metabolic information. Nonetheless, we have reported the first established metabolic profile of HUMSC. In addition, these experiments confirmed the metabolite features of adipogenic differentiation in HUMSCs by a traditional and effective method. This will, in future, provide a theoretical basis for identifying HUMSCs and monitoring their differentiation using MR spectroscopy.

ACKNOWLEDGMENTS

The majority of work in this study was carried out in the Multidisciplinary Research Center (MRC) of Shantou University. Many techniques and materials were supplied and supported by researchers in the Stem Cell Laboratory of MRC.

COMMENTS

Background

Cellular-based therapies using mesenchymal stem cells (MSCs) are being evaluated as promising treatment options for many diseases and injuries. Before clinical application, an effective method for monitoring the cell's physiological function and activity should be established. NMR spectroscopy can act as a powerful window into the metabolic machinery of cells, so that it can reflect the function and activity of the cells. However, so far, the information about metabolites of human umbilical MSCs (HUMSC) has been limited, and there are unexplored areas in this field. This project was aimed to explore the characteristic biomarkers of HUMSCs, and identify their variation after adipogenic differentiation using *in vitro* nuclear magnetic resonance (NMR) spectroscopy. This has not been reported previously.

Research frontiers

The research hotspot is to establish the metabolic profile of HUMSCs. Additionally, the results demonstrated that NMR spectroscopy would be a promising technology for identifying stem cell type and the physiological function and activity change.

Innovations and breakthroughs

In the present study, the authors report a novel strategy for investigating intracellular metabolites of HUMSCs and adipocytes using NMR spectroscopy, which allows identification of the stem cell and changes in physiological function and activity. The current study established the metabolic profile of HUMSCs, successfully. It will provide a theoretical basis for future use of NMR spectroscopy to identify HUMSCs and monitor their differentiation.

Applications

The present study not only identified the endogenous metabolites of HUMSCs, but also provided a novel strategy for stem cell identification and evaluation of physiological function and activity.

Terminology

HUMSC isolated from human umbilical cord Wharton's Jelly called fetal appendage, were considered to be a new stem cell line for cellular-based therapy. NMR spectroscopy can act as a powerful window into the metabolic machinery of cells, and it can reflect the function and activity of cells non-invasively.

Peer review

In this study the authors attempt to identify the metabolic profile of HUMSC during adipogenic differentiation by NMRs. The method which used for evaluating of differentiation is interesting.

REFERENCES

- 1 Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. *Cell Transplant* 2011; **20**: 5-14
- 2 Ma L, Feng XY, Cui BL, Law F, Jiang XW, Yang LY, Xie QD, Huang TH. Human umbilical cord Wharton's Jelly-derived mesenchymal stem cells differentiation into nerve-like cells. *Chin Med J (Engl)* 2005; **118**: 1987-1993
- 3 Mitchell KE, Weiss ML, Mitchell BM, Martin P, Davis D, Morales L, Helwig B, Beerenstrauch M, Abou-Easa K, Hildreth T, Troyer D, Medicetty S. Matrix cells from Wharton's jelly form neurons and glia. *Stem Cells* 2003; **21**: 50-60
- 4 Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. *Cell Commun Signal* 2011; **9**: 12
- 5 Xu ZF, Xiao YY, Wu RH. NMR in metabolic profiles of neural stem/progenitor cells: Current status and relevant

- problems. *Curr Med Imaging Rev* 2009; **5**: 144-149
- 6 **Haddadin IS**, McIntosh A, Meisamy S, Corum C, Styczynski Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ. Metabolite quantification and high-field MRS in breast cancer. *NMR Biomed* 2009; **22**: 65-76
 - 7 **Jansen JF**, Shablott MJ, van Zijl PC, Lehtimäki KK, Bulte JW, Gearhart JD, Hakumäki JM. Stem cell profiling by nuclear magnetic resonance spectroscopy. *Magn Reson Med* 2006; **56**: 666-670
 - 8 **Manganas LN**, Zhang X, Li Y, Hazel RD, Smith SD, Wagshul ME, Henn F, Benveniste H, Djuric PM, Enikolopov G, Malletic-Savatic M. Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain. *Science* 2007; **318**: 980-985
 - 9 **Shi C**, Wang X, Wu S, Zhu Y, Chung LW, Mao H. HRMAS 1H-NMR measured changes of the metabolite profile as mesenchymal stem cells differentiate to targeted fat cells in vitro: implications for non-invasive monitoring of stem cell differentiation in vivo. *J Tissue Eng Regen Med* 2008; **2**: 482-490
 - 10 **Cao Z**, Wu LP, Li YX, Guo YB, Chen YW, Wu RH. Change of choline compounds in sodium selenite-induced apoptosis of rats used as quantitative analysis by in vitro 9.4T MR spectroscopy. *World J Gastroenterol* 2008; **14**: 3891-3896
 - 11 **Karahuseyinoglu S**, Kocaefe C, Balci D, Erdemli E, Can A. Functional structure of adipocytes differentiated from human umbilical cord stroma-derived stem cells. *Stem Cells* 2008; **26**: 682-691
 - 12 **Xu ZF**, Shen CY, Zhu HQ, Chen YW, Wu LP, Huang P, Xiao YY, Shen ZW, Pang L, Guo XQ, Ma L, RH Wu. Is 1.28 parts per million biomarker specific for neural progenitor cells? *Neural Regen Res* 2010; **5**: 1125-1129
 - 13 **Schmitz JE**, Kettunen MI, Hu DE, Brindle KM. 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. *Magn Reson Med* 2005; **54**: 43-50
 - 14 **Iorio E**, Di Vito M, Spadaro F, Ramoni C, Lococo E, Carnevale R, Lenti L, Strom R, Podo F. Triacsin C inhibits the formation of 1H NMR-visible mobile lipids and lipid bodies in HuT 78 apoptotic cells. *Biochim Biophys Acta* 2003; **1634**: 1-14
 - 15 **Soares DP**, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. *Clin Radiol* 2009; **64**: 12-21
 - 16 **Martínez-Bisbal MC**, Martí-Bonmatí L, Piquer J, Revert A, Ferrer P, Llácer JL, Piotta M, Assemat O, Celda B. 1H and 13C HR-MAS spectroscopy of intact biopsy samples ex vivo and in vivo 1H MRS study of human high grade gliomas. *NMR Biomed* 2004; **17**: 191-205
 - 17 **Di Vito M**, Lenti L, Knijn A, Iorio E, D'Agostino F, Molinari A, Calcabrini A, Stringaro A, Meschini S, Arancia G, Bozzi A, Strom R, Podo F. 1H NMR-visible mobile lipid domains correlate with cytoplasmic lipid bodies in apoptotic T-lymphoblastoid cells. *Biochim Biophys Acta* 2001; **1530**: 47-66
 - 18 **Gasparovic C**, Rosenberg GA, Wallace JA, Estrada EY, Roberts K, Pastuszyn A, Ahmed W, Graham GD. Magnetic resonance lipid signals in rat brain after experimental stroke correlate with neutral lipid accumulation. *Neurosci Lett* 2001; **301**: 87-90
 - 19 **Hansen JB**, Petersen RK, Larsen BM, Bartkova J, Alsner J, Kristiansen K. Activation of peroxisome proliferator-activated receptor gamma bypasses the function of the retinoblastoma protein in adipocyte differentiation. *J Biol Chem* 1999; **274**: 2386-2393
 - 20 **Sitter B**, Sonnewald U, Spraul M, Fjösne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. *NMR Biomed* 2002; **15**: 327-337
 - 21 **Govindaraju V**, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. *NMR Biomed* 2000; **13**: 129-153

S- Editor Wang JL L- Editor Hughes D E- Editor Zheng XM

Acknowledgments to reviewers of *World Journal of Stem Cells*

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Stem Cells*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

Markus Frank, MD, Assistant Professor, Harvard Medical School, Transplantation Research Center, Children's Hospital Boston, Enders Research Building Room 816, 300 Longwood Avenue, Boston, MA 02115, United States

Alice Pébay, PhD, Centre for Neuroscience and Department of Pharmacology, University of Melbourne, Parkville VIC 3010, Australia

Zhong-Chao Han, MD, PhD, Professor, Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China

Hiroyuki Miyoshi, PhD, Subteam for Manipulation of Cell Fate, BioResourceCenter, RIKEN, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

Heli Teija Kristiina Skottman, PhD, Academy of Finland Research fellow, Regea Institute for Regenerative medicine, University of Tampere, Finland, Biokatu 12, 33520 Tampere, Finland

Soren Paludan Sheikh, MD, PhD, Professor, Department of Biochemistry, Pharmacology and Genetics, Odense Univer-

sity Hospital, University of Southern Denmark, Sdr. Boulevard 29, DK 5000, Denmark

Ludwig Aigner, PhD, Professor, Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Strubergasse 21, A-5020 Salzburg, Austria

Borhane Annabi, PhD, Professor, Department of Chemistry, Biomed Research Centre, Université du Québec à Montréal Montreal, Quebec, H2X 2J6, Canada

Denis Corbeil, PhD, Tissue Engineering Laboratories, Biotech, Medical Faculty, Technical University of Dresden, Tatzberg 47-49, 01307 Dresden, Germany

Mieke Geens, PhD, EMGE, UZ Brussel, Laarbeeklaan 101, 1090 Jette, Brussels, Belgium

Xiao-Yan Jiang, MD, PhD, Associate Professor, Medical Genetics, University of British Columbia, Senior Scientist, Terry Fox Laboratory, BC Cancer Agency Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada

John F Zhong, PhD, Assistant Professor, School of Medicine, University of Southern California, 2025 Zonal Ave, RMR 210, Los Angeles, CA 90033, United States

Hong Yu, PhD, Miami VA Health Care System, 1201 NW 16th St, Research 151, Miami, FL 33125, United States

Andre Van Wijnen, PhD, Department of Cell Biology, Rm S3-322, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, United States

Events Calendar 2012

January 22-27, 2012

Keystone Symposia: Cardiovascular
 Development and Regeneration
 Taos, NM, United States

February 2-3, 2012

Stem Cells 2012
 San Diego, CA, United States

February 16, 2012

The 2012 London Regenerative
 Medicine Event
 London, United Kingdom

February 23, 2012

CiRA Symposium: Advances in
 Nuclear Reprogramming and Stem
 Cell Research
 Kyoto, Japan

February 26 - March 2, 2012

Gordon Research Conference:
 Reprogramming Cell Fate
 Galveston, TX, United States

March 9, 2012

Cell Culture Technology: Recent
 Advances, Future Prospects
 London, United Kingdom

March 11-16, 2012

Keystone Symposia: The Life of a
 Stem Cell: From Birth to Death
 Olympic Valley (Lake Tahoe),
 CA, United States

March 25-30, 2012

Keystone Symposia: Advances in
 Islet Biology
 Monterey, CA, United States

March 28-29, 2012

Single Cell Analysis Europe
 Edinburgh, United Kingdom

April 1 - 6, 2012

Keystone Symposia: Mechanisms
 of Whole Organ Regeneration,
 joint with Regenerative Tissue
 Engineering and Transplantation
 Breckenridge, CO, United States

April 25-28, 2012

3rd International Congress on
 Responsible Stem Cell Research
 Aula Nuova del Sinodo
 Vatican City, Vatican City

April 27-29, 2012

2nd Institute of Advanced Dental
 Sciences & Research International
 Conference 2012: Fundamentals of
 Conducting and Reporting Research-
 Biological, Pharmaceutical, Medical
 & Dental Sciences
 University of the Punjab, Lahore,
 Pakistan

April 29 - May 2, 2012

3rd International Conference on
 Stem Cell Engineering (ICSCE)
 Co-organized by the Society for
 Biological Engineering (SBE) and the
 ISSCR
 Seattle, WA, United States

April 30, 2012

Stem Cells to Tissues
 Boston, MA, United States

April 30, 2012

Regenerative Biology: From Stem
 Cells to Tissues
 The Joseph B Martin Conference
 Center, Harvard Medical School
 Boston, MA, United States

April 30-May 2, 2012

Till & McCulloch Meetings
 Montreal, QC, Canada

May 18, 2012

The 2012 Stem Cell Discussion
 Forum
 London, United Kingdom

May 21-22, 2012

Driving Stem Cell Research Towards
 Therapy.
 Edinburgh, United Kingdom

June 5-8, 2012

18th Annual International Society
 for Cellular Therapy Meeting
 Washington, DC, United States

June 13-16, 2012

International Society for Stem Cell
 Research 10th Annual Meeting
 Yokohama, Japan

June 25-27, 2012

The Stem Cell Niche - development
 and disease
 Copenhagen, Denmark

June 27-28, 2012

Bioprocessing & Stem Cells Europe
 London, United Kingdom

June 28-29, 2012

Origins of Tissue Stem Cells
 Edinburgh, United Kingdom

July 9-11, 2012

Stem Cells in Cancer - 2nd annual
 Cambridge Stem Cell International
 Symposium
 Cambridge, United Kingdom

July 15-18, 2012

39th Annual Meeting & Exposition
 of the Controlled Release Society
 Smart Materials - From Innovation
 to Translation
 Centre des Congrès de Québec,
 Québec City, Canada

August 29 - September 1, 2012

EMBL Conference: Stem Cells in
 Cancer and Regenerative Medicine
 Heidelberg, Germany

September 5-8, 2012

TERMIS World Congress 2012
 Vienna, Austria

October 15-17 2012

13th World Congress of the
 International Society for Diseases of
 the Esophagus
 Venice, Italy

November 6, 2012

Stem Cells and Metabolism
 The Salk Institute of Biological
 Studies La Jolla,
 CA, United States

GENERAL INFORMATION

World Journal of Stem Cells (*World J Stem Cells*, *WJSC*, online ISSN 1948-0210, DOI: 10.4252), is a monthly, open-access (OA), peer-reviewed journal supported by an editorial board of 284 experts in stem cell from 28 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJSC* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article *via* online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJSC* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJSC* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality ar-

ticles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

Aims and scope

The major task of *WJSC* is to report rapidly original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including: Embryonic, neural, hematopoietic, mesenchymal, tissue-specific, and cancer stem cells; the stem cell niche; stem cell genomics and proteomics; and stem cell techniques and their application in clinical trials. Papers published in *WJSC* will cover the biology, culture, differentiation and application of stem cells from all stages of their development, from germ cell to embryo and adult.

Columns

The columns in the issues of *WJSC* will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in stem cells; (9) Brief Articles: To briefly report the novel and innovative findings in stem cells; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in *WJSC*, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of stem cells; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in stem cells.

Name of journal

World Journal of Stem Cells

ISSN

ISSN 1948-0210 (online)

Editor-in-Chief

Oscar Kuang-Sheng Lee, MD, PhD, Professor, Medical Research and Education of Veterans General Hospital-Taipei, No. 322, Sec. 2, Shih-pai Road, Shih-pai, Taipei, 11217, Taiwan, China

Editorial Office

World Journal of Stem Cells

Editorial Department: Room 903, Building D,
Ocean International Center, No. 62 Dongsihuan Zhonglu,
Chaoyang District, Beijing 100025, China

Instructions to authors

E-mail: wjsc@wjgnet.com
<http://www.wjgnet.com>
Telephone: +86-10-85381891
Fax: +86-10-85381893

Indexed and Abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

Published by

Baishideng Publishing Group Co., Limited

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJSC* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines

Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/1948-0210office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/1948-0210/g_info_20100313165700.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjsc@wjgnet.com, or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJSC*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no less than 256 words) and

structured abstracts (no less than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no less than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/..."; MATERIALS AND METHODS (no less than 140 words); RESULTS (no less than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$; CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: http://www.wjgnet.com/1948-0210/g_info_list.htm.

Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ... *etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* < 0.05, ^b*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, ^c*P* < 0.05 and ^d*P* < 0.01 are used. A third series of *P* values can be expressed as ^e*P* < 0.05 and ^f*P* < 0.01. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine con-

Instructions to authors

tributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Pleased provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMCID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as ν (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pres-

sure, p (B) = 16.2/12.3 kPa; incubation time, t (incubation) = 96 h, blood glucose concentration, c (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, p (CEA) = 8.6 24.5 μ g/L; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantumms can be found at: http://www.wjgnet.com/1948-0210/g_info_20100313172144.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: t time or temperature, c concentration, A area, l length, m mass, V volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindIII*, *BamHI*, *Kbo I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

Examples for paper writing

Editorial: http://www.wjgnet.com/1948-0210/g_info_20100313165833.htm

Frontier: http://www.wjgnet.com/1948-0210/g_info_20100313170509.htm

Topic highlight: http://www.wjgnet.com/1948-0210/g_info_20100313170618.htm

Observation: http://www.wjgnet.com/1948-0210/g_info_20100313170727.htm

Guidelines for basic research: http://www.wjgnet.com/1948-0210/g_info_20100313170855.htm

Guidelines for clinical practice: http://www.wjgnet.com/1948-0210/g_info_20100313171012.htm

Review: http://www.wjgnet.com/1948-0210/g_info_20100313171124.htm

Original articles: http://www.wjgnet.com/1948-0210/g_info_20100313171239.htm

Brief articles: http://www.wjgnet.com/1948-0210/g_info_20100313171358.htm

Case report: http://www.wjgnet.com/1948-0210/g_info_20100313171504.htm

Letters to the editor: http://www.wjgnet.com/1948-0210/g_info_20100313171613.htm

Book reviews: http://www.wjgnet.com/1948-0210/g_info_20100313171713.htm

Guidelines: http://www.wjgnet.com/1948-0210/g_info_20100313171803.htm

SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJSC*. The revised version including manuscript and high-resolution image figures (if any) should be re-submitted online (<http://www.wjgnet.com/1948-0210office/>). The author should send the copyright transfer letter, responses to the reviewers, English language Grade B certificate (for non-native speakers of English) and final manuscript checklist to wjsc@wjgnet.com.

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/1948-0210/g_info_20100313172045.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/1948-0210/g_info_20100313172000.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJSC will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

Publication fee

WJSC is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article. Editorial, topic highlights, original articles, brief articles, book reviews and letters to the editor are published free of charge.